USE OF EphA4 AND MODULATOR OF EphA4 FOR DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and agonize EphA4. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that preferentially binds to an EphA4 epitope that is exposed on cancer cells but not non-cancer cells. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 with a very low Koff to reduce EphA4 expression and, thereby, inhibit tumor cell growth and / or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA4 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

Description

[0001]This application claims priority to U.S. Provisional Patent application No. 60 / 476,909, filed Jun. 6, 2003, and U.S. Provisional Patent application No. 60 / 503,356, filed Sep. 16, 2003, each of which is incorporated by reference herein in its entirety.1. FIELD OF THE INVENTION[0002]The present invention relates to methods and compositions designed for the treatment, management, or prevention of hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies specific for EphA4, preferably monoclonal antibodies, that are EphA4 agonists, inhibit a cancer cell phenotype (such as colony formation in soft agar or tubular network formation in a three dimensional basement membrane or extracellular membrane preparation, such as MATRIGEL™), preferentially bind epitopes on EphA4 that are selectively exposed or increased on cancer cells but not non-cancer cells and / or bind EphA4 with a Koff of l...

AI Technical Summary

Benefits of technology

[0015]In addition, cancer cells exhibit phenotypic traits that differ from those of non-cancer cells, for example, formation of colonies in a three-dimensional substrate such as soft agar or the formation of tubular networks or weblike matrices in a three-dimensional basement membrane or extracellular matrix preparation, such as MATRIGEL™. Non-cancer cells do not form colonies in soft agar and form distinct sphere-like structures in three-dimensional basement membrane or extracellular matrix preparations. The present inventors have also found that anti-EphA4 antibodies can reduce growth of EphA4-expressing cancer cells in soft agar. Accordingly, the invention also provides antibodies that specifically bind EphA4 and inhibit one or more cancer cell phenotypes, such as colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparations (“cancer cell phenotype inhibitory EphA4 antibodies”). Exposing cancer cells to such cancer cell phenotype inhibitory EphA4 antibodies prevents or decreases the cells' ability to colonize or form tubular networks in these substrates. Furthermore, in certain embodiments, the addition of such cancer cell phenotype inhibitory EphA4 antibodies to already established colonies of cancer cells cause a reduction or elimination of an existing cancer cell colony, i.e., leads to killing of hyperproliferative and / or metastatic cells, for example through necrosis or apoptosis.

[0017]Antibodies that bind EphA4 with a very low Koff rate may be particularly effective to reduce EphA4 expression and / or induce EphA4 degradation and, thereby, inhibit tumor cell growth and / or metastasis and / or proliferation of hyperproliferative cells. Accordingly, the invention further provides antibodies that bind EphA4 with a Koff of less than 3×10−3 s−1 and, preferably, are EphA4 agonists.

[0056]As used herein, the terms “treat,”“treating” and “treatment” refer to the eradication, reduction or amelioration of symptoms of a disease or disorder, particularly, the eradication, removal, modification, or control of primary, regional, or metastatic cancer tissue that results from the administration of one or more therapeutic agents. In certain embodiments, such terms refer to the minimizing or delaying the spread of cancer resulting from the administration of one or more therapeutic agents to a subject with such a disease.

[0058]As used herein, a “therapeutically effective amount” refers to that amount of the therapeutic agent sufficient to treat or manage a disease or disorder associated with EphA4 overexpression and / or cell hyperproliferative disease and, preferably, the amount sufficient to destroy, modify, control or remove primary, regional or metastatic cancer tissue. A therapeutically effective amount may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of the hyperproliferative disease, e.g., delay or minimize the spread of cancer. A therapeutically effective amount may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of cancer. Further, a therapeutically effective amount with respect to a therapeutic agent of the invention means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of hyperproliferative disease or cancer. Used in connection with an amount of an EphA4 antibody of the invention, the term can encompass an amount that improves overall therapy, reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapeutic agent.

Problems solved by technology

However, cancer cells generally display decreased cell-cell contacts and this may decrease EphA4-ligand binding.

Furthermore, the overexpression of EphA4 may cause an excess of EphA4 relative to ligand that increases the amount of non-ligand bound EphA4.

Additionally, EphA4 may have altered ligand binding properties (e.g., due to an altered conformation) in cancer cells such that it is incapable of stable interactions with its ligand whether or not it is localized to the cell-cell junction.

Images